J. Elkins

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
J. S. Elkins, J. Elkins, Jacob S Elkins, J S Elkins, Jacob S. Elkins, J Elkins, Jacob Elkins
Publication record
86 papers · 2,990 citations · H-index 28

PAPERS

Post‐stroke blood–brain barrier disruption predicts poor outcome in patients enrolled in the ACTION study
202111 citationsauthor #4
Safety and Efficacy of Natalizumab as Adjunctive Therapy for People With Drug-Resistant Epilepsy
202112 citationsauthor #15
Natalizumab in acute ischemic stroke (ACTION II)
202076 citationsauthor #10
Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis clinical trials.
20195 citationsauthor #6
Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
201841 citationsauthor #13
Exposure–disease response analysis of natalizumab in subjects with multiple sclerosis
20178 citationsauthor #6
Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta: A Prospective, Open-Label, Single-Arm Study.
20179 citationsauthor #5
Exposure–disease response analysis of natalizumab in subjects with multiple sclerosis
20170 citationsauthor #6
Prolonged-Release Fampridine Induces Sustained Clinically Meaningful Improvements in Walking Ability in People with Multiple Sclerosis: Results from the ENHANCE Trial (P6.364)
20173 citationsauthor #11
Cells during CD25 Blockade In Vivo Maintenance of Human Regulatory T
20170 citationsauthor #2
Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study
201742 citationsauthor #7
Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial.
2017184 citationsauthor #1
Effects of Daclizumab HYP on Accumulation of Disability Exclusive of Acute Relapse in Moderately/Severely Disabled Relapsing-Remitting Multiple Sclerosis Patients: Neurophysical Composite Outcome from the DECIDE Study (P3.085)
20160 citationsauthor #10
Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach.
201622 citationsauthor #4
Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial
201658 citationsauthor #10
Reversible Effects of Daclizumab HYP on Lymphocyte Counts in RRMS Patients: Data from the SELECT Trilogy Studies (P5.281)
20162 citationsauthor #7
Daclizumab high‐yield process reduced the evolution of new gadolinium‐enhancing lesions to T1 black holes in patients with relapsing−remitting multiple sclerosis
20168 citationsauthor #10
Improved Cognitive Outcomes in Relapsing-Remitting Multiple Sclerosis with Daclizumab HYP Over 96 Weeks in the Phase 3 DECIDE Study (P3.090)
20163 citationsauthor #6
Natalizumab Versus Placebo in Patients with Acute Ischemic Stroke (AIS): Results from ACTION, a Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase 2 Clinical Trial (S7.005)
20166 citationsauthor #1
Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies.
201654 citationsauthor #9
Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis
201635 citationsauthor #11
Tentative and Confirmed Disability Progression in MS Clinical Trials (P2.115)
20160 citationsauthor #1
Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis
20161 citationsauthor #5
Sustained clinically meaningful improvements in walking ability with prolonged-release fampridine: results from the placebo-controlled ENHANCE study.
20163 citationsauthor #11
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
201639 citationsauthor #13
Treatment with Daclizumab HYP Improved Disease-Specific Patient-Reported Outcomes Versus Interferon Beta-1a in Multiple Sclerosis in the Phase 3 DECIDE Trial (P7.209)
20150 citationsauthor #7
Daclizumab High-Yield Process (DAC HYP) has no Effect on Activity of the Cytochrome P450 (CYP) Enzymes: Results of a Drug Cocktail Interaction Study in Subjects with Multiple Sclerosis (MS) (P1.148)
20151 citationsauthor #5
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
2015247 citationsauthor #13
Identifying a Minimally Important Change Threshold for The Multiple Sclerosis Walking Scale-12 (MSWS-12)
20150 citationsauthor #8
Evaluation of Immunogenicity in Patients with Multiple Sclerosis Treated with Daclizumab HYP (P1.147)
20151 citationsauthor #6
Daclizumab HYP Reduced Brain MRI Lesion Activity Compared With Interferon Beta-1a: Results from the DECIDE Study (P7.252)
20152 citationsauthor #12
Long-Term Safety of Daclizumab HYP in Patients with Relapsing-Remitting Multiple Sclerosis: 3-4 Year Results from the SELECTED Extension Study (P7.225)
20151 citationsauthor #11
Safety and Tolerability Results From the DECIDE Study: A Phase 3 Active-Comparator Study of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis (P7.230)
20155 citationsauthor #12
Daclizumab HYP Versus Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis: Primary Results of the DECIDE Study (S4.003)
20157 citationsauthor #12
CD56bright natural killer cells and response to daclizumab HYP in relapsing-remitting MS
201538 citationsauthor #1
Early, Sustained and Reversible Pharmacodynamic Effects of Daclizumab HYP in MS Support Mechanism of Action via Modulation of the IL-2 Pathway (P1.149)
20152 citationsauthor #5
Pharmacokinetics of Daclizumab High-Yield Process (DAC HYP) with Repeated Administration of the Clinical Subcutaneous Regimen in Subjects With Relapsing-Remitting Multiple Sclerosis (P3.257)
20152 citationsauthor #6
Identifying an important change estimate for the Multiple Sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial results
201545 citationsauthor #8
Letter by Elkins et al regarding article, "blocking of α4 integrin does not protect from acute ischemic stroke in mice".
20141 citationsauthor #1
Reduction in Brain Atrophy with Extended Daclizumab HYP Treatment: Results of SELECT and the SELECT Extension Study (P3.187)
20141 citationsauthor #6
Psychometric Properties of the MSIS-29 and Factors Predicting Score Changes in Clinical Trials: An Analysis of Data from the SELECT Study (P3.131)
20141 citationsauthor #5
In Vivo Maintenance of Human Regulatory T Cells during CD25 Blockade
201451 citationsauthor #8
Disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study
201427 citationsauthor #8
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
201497 citationsauthor #11
Evaluation of Immunogenicity in Multiple Sclerosis Patients Treated with Daclizumab-HYP During the SELECT and SELECTION Clinical Trials (P3.177)
20140 citationsauthor #6
Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening
201456 citationsauthor #7
Decrease in T1 Black Hole Volume Over 2 Years of Daclizumab High-Yield Process Treatment (P3.188)
20142 citationsauthor #1
CD25 blockade with daclizumab alters regulatory T cell dynamics in RRMS patients (THER3P.880)
20140 citationsauthor #8
Proportion of Disease-Activity Free Patients with Relapsing-Remitting Multiple Sclerosis Following 1 Year of Treatment with Daclizumab High-Yield Process in the SELECT Study (P07.105)
20132 citationsauthor #7
Daclizumab High-Yield Process Treatment Reduced the Impact of Multiple Sclerosis Relapse on Health-Related Quality of Life (Results of the SELECT Trial) (P03.212)
20131 citationsauthor #4
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
2013289 citationsauthor #11
Regulatory T-Cell Numbers in Patients with Relapsing-Remitting MS Were Not Associated with Clinical or MRI Outcomes in the SELECT Study (P05.192)
20131 citationsauthor #7
Daclizumab HYP Reduces the Evolution of New Gadolinium-Enhancing Lesions to T1-Black Holes: Results from the SELECT Study (P07.094)
20131 citationsauthor #7
Reversal of the Pharmacodynamic Effects of Daclizumab HYP Following Treatment Washout: Results from the SELECTION Study (P05.188)
20135 citationsauthor #8
The Safety and Efficacy of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis in the SELECTION Extension Study: Primary Results (S01.001)
20134 citationsauthor #10
Responder Definition of the Multiple Sclerosis Impact Scale (MSIS-29) Physical Impact Scale for Patients with Physical Worsening (P01.207)
20130 citationsauthor #3
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
201319 citationsauthor #7
A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Daclizumab HYP Monotherapy in Relapsing-Remitting Multiple Sclerosis: Primary Results of the SELECT Trial (S01.005)
201224 citationsauthor #10
CD56bright Natural Killer Cell Expansion Predicts Response to Daclizumab HYP Treatment in RRMS: Results of the SELECT Trial (S31.004)
20128 citationsauthor #1
Daclizumab HYP Monotherapy Improved Health-Related Quality of Life Parameters in Relapsing-Remitting Multiple Sclerosis: Findings of the SELECT Trial (P07.098)
20122 citationsauthor #6
Intermediate-affinity interleukin-2 receptor expression predicts CD56bright natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis
201151 citationsauthor #9
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
2010314 citationsauthor #6
Perfusion-CT assessment of the cerebrovascular reserve: a revisit to the acetazolamide challenges.
200823 citationsauthor #2
Neurological Complications of Hypertension
20080 citationsauthor #2
Methylenetetrahydrofolate reductase C677T polymorphism and cognitive function in older women.
200739 citationsauthor #1
Contribution Methylenetetrahydrofolate Reductase C 677 T Polymorphism and Cognitive Function in Older Women
20071 citationsauthor #1
Atherosclerosis and dementia: Leading by association
20070 citationsauthor #1
Cross-validation of a simple 3-point prediction rule to stratify 7-day stroke risk after TIA
20060 citationsauthor #5
Effect of a US National Institutes of Health programme of clinical trials on public health and costs.
2006180 citationsauthor #5
Education and the cognitive decline associated with MRI-defined brain infarct
2006120 citationsauthor #1
Pre‐existing hypertension and the impact of stroke on cognitive function
200519 citationsauthor #1
Cognitive function predicts first-time stroke and heart disease
200575 citationsauthor #1
Twinning hearts and minds
20044 citationsauthor #1
Regionalization of Treatment for Subarachnoid Hemorrhage
20041 citationsauthor #3
Stroke risk factors and loss of high cognitive function
200452 citationsauthor #1
Regionalization of Treatment for Subarachnoid Hemorrhage: A Cost-Utility Analysis
200473 citationsauthor #3
Pediatric Stroke Belt: Geographic Variation in Stroke Mortality in US Children
200439 citationsauthor #2
Alzheimer disease risk and genetic variation in ACE
2004117 citationsauthor #1
Thirty-year projections for deaths from ischemic stroke in the United States.
200391 citationsauthor #1
Head Computed Tomography Findings Predict Short-Term Stroke Risk After Transient Ischemic Attack
2003132 citationsauthor #3
The Importance of the Electrocardiogram in TIA Evaluation
20011 citationsauthor #1
Coding Neuroradiology Reports for the Northern Manhattan Stroke Study: A Comparison of Natural Language Processing and Manual Review
200055 citationsauthor #1
Clinical Pharmacology: Advances and Applications Dovepress Pharmacokinetics of Daclizumab High-yield Process with Repeated Administration of the Clinical Subcutaneous Regimen in Patients with Relapsing- Remitting Multiple Sclerosis
year unknown12 citationsauthor #5
A randomized, placebo-controlled trial
year unknown0 citationsauthor #10
CD56 bright natural killer cells and response to daclizumab HYP in relapsing-remitting MS
year unknown25 citationsauthor #1
Conclusions: Cd56
year unknown0 citationsauthor #1

TIMELINE

2000 55 citations

2001 1 citations

2003 223 citations

2004 286 citations

2005 94 citations

2006 300 citations

2007 40 citations

2008 23 citations

2010 314 citations

2011 51 citations

2012 34 citations

2013 322 citations

2014 236 citations

2015 351 citations

2016 231 citations

2017 246 citations

2018 41 citations

2019 5 citations

2020 76 citations

2021 23 citations

Unknown 37 citations

J. Elkins

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT